Know Cancer

or
forgot password

A Phase I Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma Patients


Phase 1
18 Years
N/A
Not Enrolling
Both
Renal Cell Carcinoma, Kidney Cancer

Thank you

Trial Information

A Phase I Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma Patients


To assess the maximum tolerated doses and overall safety and tolerability of Sunitinib
administered in combination with RAD001 for the treatment of patients with metastatic renal
cell carcinoma.

To assess antitumor activity of the combination of Sunitinib and RAD001.

This study is designed to confirm that the 2 agents can be administered safely in
combination. Patients will begin treatment with Sunitinib and RAD001 on Day 1. RAD001 will
be administered orally on a weekly schedule. Sunitinib will be given orally on a 4 weeks on,
2 weeks off schedule. DLT determination will be based on toxicities observed in Cycle 1 - a
cycle is defined by Sunitinib dosing ( 6 weeks). Once the MTD for the combination has been
identified, a total of 10 patients will be enrolled at the highest dose level that allows
for administration of multiple cycles and provides potentially therapeutic drug levels of
both drugs to further assess safety and tolerability and to obtain a preliminary assessment
of efficacy. Patients will be treated with RAD001 and Sunitinib until there is disease
progression, significant toxicity or withdrawal of patient consent. Patients judged to
derive benefit from treatment would be offered participation in a continuation protocol at
the conclusion of this study.


Inclusion Criteria:



- Any histologically confirmed renal cell carcinoma with metastases. Patients with
unresected primary tumors may be enrolled as long as evidence of metastatic disease
is also present.

- No prior sunitinib or m-TOR inhibitor. The washout period must be at least 4 weeks
for any prior therapy.

- Male or female, 18 years of age or older.

- ECOG performance status 0 or 1.

- Resolution of all acute toxic effects of prior chemotherapy, radiotherapy, or
surgical procedure to NCI CTCAE grade less than or equal to 1.

- Adequate organ function as defined by the following criteria:

- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT])
and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) less
than or equal to 2.5 x upper limit of normal (ULN) or less than 5 x ULN in the
presence of liver metastases.

- Total serum bilirubin less than or equal to 1.5 mg/dL

- Total leukocyte count greater to or equal to 3000 cells/ul

- Absolute neutrophil count (ANC) greater than or equal to 1500/µL

- Platelets greater than or equal to 100,000/µL

- Hemoglobin greater than or equal to 9.0 g/dL

- Serum calcium less than or equal to 12.0 mg/dL

- Serum creatinine less than or equal to 2.0 x ULN

- PT less than or equal to 1.5 ULN

- Negative serum or urine pregnancy test in women of child-bearing age

- Signed and dated informed consent document indicating that the patient (or legally
acceptable representative) has been informed of all pertinent aspects of the trial
prior to enrollment.

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests, and other study procedures.

Exclusion Criteria:

- Major surgery, open biopsy, traumatic injury, radiation or systemic therapy within 4
weeks of starting the study treatment. Anticipation of major surgical procedure
during the study. Prior palliative radiotherapy to metastatic lesion(s)is permitted,
provided there is at least one measurable lesion that has not been irradiated.

- More than 3 prior systemic therapies for metastatic RCC.

- Minor surgical procedures such as fine needle aspirations or core biopsies within 7
days prior to Day 0.

- No other approved or investigational anticancer treatment will be permitted during
the study period, including chemotherapy, biological response modifiers, hormone
therapy, or immunotherapy, with the exception of palliative radiation therapy. No
other investigational drug may be used during treatment on this protocol, and
concurrent participation in another clinical trial is not allowed.

- NCI CTCAE grade 3 hemorrhage within the past 1 month.

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to Day 0.

- Chronic treatment with systemic steroids or other immunosuppressive agent

- Uncontrolled brain or leptomeningeal metastases, including patients who continue to
require glucocorticoids for brain or leptomeningeal metastases

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of Sunitinib or RAD001 (e.g. malabsorptive
disorder, ulcerative disease, uncontrolled nausea, vomiting, diarrhea, or small bowel
resection)

- Patients with an active bleeding diathesis or on oral anti-vitamin K medication
(except low dose warfarin)

- Current spinal cord compression, or carcinomatous meningitis.

- Any of the following within the 12 months prior to study drug administration:

- severe/unstable angina,

- MI,

- CABG,

- symptomatic congestive heart failure,

- cerebrovascular accident or transient ischemic attack or peripheral vascular
disease.

- Ongoing cardiac dysrhythmias of NCI CTCAE grade greater or equal to 2, atrial
fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males
and >470 msec for females.

- Blood pressure > 150/100mmHg

- Evidence of bleeding diathesis or coagulopathy

- Serious, non-healing wound, ulcer or bone fracture

- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness.

- Current treatment on another therapeutic clinical trial.

- Pregnancy or breastfeeding. Female patients must be surgically sterile or be
postmenopausal, or must agree to use effective contraception during the period of
therapy.

- Male patients must be surgically sterile or must agree to use effective contraception
during the period of therapy. The definition of effective contraception will be based
on the judgment of the principal investigator or a designated associate.

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, or may interfere with the interpretation of study results, and
in the judgment of the investigator would make the patient inappropriate for entry
into this study.

- Receipt of any investigational agent within 4 weeks prior to study entry.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the maximum tolerated doses and overall safety and tolerability of Sunitinib administered in combination with RAD001 for the treatment of patients with metastatic renal cell carcinoma.

Outcome Time Frame:

toxicities observed in Cycle 1 - a cycle is defined by Sunitinib dosing ( 6 weeks)

Safety Issue:

Yes

Principal Investigator

Glenn Kroog, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

06-105

NCT ID:

NCT00422344

Start Date:

October 2006

Completion Date:

February 2010

Related Keywords:

  • Renal Cell Carcinoma
  • Kidney Cancer
  • RAD001
  • Sunitinib
  • renal
  • kidney
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer Center 1275 York AvenueNew York, New York  10021